Valuation: Cyclopharm Limited

Market Cap 73.75M 51.94M 44.98M 41.92M 38.46M 72.78M 4.96B 494M 194M 2.47B 195M 191M 8.19B P/E 2026 *
-3.95x
P/E 2027 * -8.46x
Enterprise Value 73.75M 51.94M 44.98M 41.92M 38.46M 72.78M 4.96B 494M 194M 2.47B 195M 191M 8.19B EV / Sales 2026 *
2.01x
EV / Sales 2027 * 1.6x
Free-Float
58.05%
Yield 2026 *
-
Yield 2027 * -
1 week+4.46%
1 month+17.00%
3 months-19.31%
6 months-50.00%
Current year-40.31%
1 week 0.52
Extreme 0.52
0.65
1 month 0.46
Extreme 0.46
0.66
Current year 0.45
Extreme 0.45
1.29
1 year 0.45
Extreme 0.45
1.29
3 years 0.45
Extreme 0.45
3.15
5 years 0.45
Extreme 0.45
3.15
10 years 0.45
Extreme 0.45
3.45
Manager TitleAgeSince
Chief Executive Officer 60 2009-10-20
Director of Finance/CFO - 2024-02-25
Chief Operating Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 60 2008-06-02
Director/Board Member 65 2021-08-09
Director/Board Member - 2022-08-31
Date Insider Type Main position Quantity % Market Cap.
3/12/26 Buy

Chief Executive Officer

10,526 0.0087%
2/26/25 Buy

Director

13,500 0.0121%
2/26/25 Buy

Chairman

8,874 0.0080%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+4.46%-43.75%-75.00% 51.77M
-0.43%+1.06%+24.03%+5.21% 212B
-0.61%+1.82%-1.07%-23.54% 137B
+0.10%+4.69%-26.86%+9.07% 125B
+1.59%+5.60%-55.67%-9.94% 69.46B
-0.98%+4.16%+8.50%+4.90% 49.56B
-0.91%+5.13%-20.61%-29.50% 47.2B
-0.25%-0.14%+21.91%+12.97% 39.08B
-0.79%+0.70%+29.97%+37.50% 37.05B
+0.00%+5.67%+116.67%+8.35% 30.97B
Average -0.23%+3.27%+5.31%-6.00% 74.76B
Weighted average by Cap. -0.24%+2.77%+3.69%-0.90%

Financials

2026 *2027 *
Net sales 36.6M 25.77M 22.32M 20.8M 19.09M 36.12M 2.46B 245M 96.12M 1.23B 96.84M 94.71M 4.07B 46.2M 32.54M 28.18M 26.26M 24.09M 45.59M 3.1B 309M 121M 1.55B 122M 120M 5.13B
Net income -18.9M -13.31M -11.53M -10.74M -9.86M -18.65M -1.27B -126M -49.64M -633M -50.01M -48.91M -2.1B -9.9M -6.97M -6.04M -5.63M -5.16M -9.77M -665M -66.25M -26M -332M -26.19M -25.62M -1.1B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
109
Date Price Change Volume
26-07-31 A$0.5850 -.--% 828
26-07-30 A$0.5850 -1.68% 35,655
26-07-29 A$0.5950 +14.42% 188,038
26-07-28 A$0.5200 -3.70% 13,755
26-07-27 A$0.5400 -3.57% 5,865
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4106USD
Average target price
0.6940USD
Spread / Average Target
+69.00%

Quarterly revenue - Rate of surprise